Clostridioides difficile Infection in Patients Undergoing Acid-Suppressive Treatment: A Large Cohort Study with Propensity Score Matching
Abstract
Abstract Introduction: Clostridioides difficile infection (CDI) is a significant concern in patients undergoing acid-suppressive therapy. This study aimed to evaluate and compare the risk of CDI in patients treated with proton pump inhibitors (PPIs), histamine 2 receptor antagonists (H2RAs), and potassium-competitive acid blockers (tegoprazan). Methods: This retrospective observational cohort study evaluated 606,460 individuals who were prescribed PPIs, H2RAs, or tegoprazan for more than 7 days, resulting in 22,431 matched individuals after propensity score matching. The primary outcome was CDI incidence within 12 weeks of medication use. Results: Patients receiving PPIs exhibited a significantly higher relative risk (RR) (RR: 1.86; 95% confidence interval [CI]: 1.18–2.91) of developing CDI than those receiving H2RAs. Tegoprazan showed no significant increase in CDI risk (RR: 1.07; 95% CI: 0.64–1.79) compared to H2RAs. The risk of CDI increased with a longer duration of acid suppressant use. No dose-dependent differences in CDI occurrence were observed across PPI doses and no significant differences were found in the incidence of severe CDI among the groups. Conclusions: PPIs are associated with a higher risk of CDI than H2RAs. These findings highlight the need for careful selection of acid-suppressive therapies, particularly in high-risk populations.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 606,460 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.